Atara Biotherapeutics Awaits FDA Decision on Tab-cel® BLA with PDUFA Target Date Set for January 10, 2026, Potential $40 Million Milestone from Pierre Fabre Laboratories

Reuters
08/12
<a href="https://laohu8.com/S/ATRA">Atara Biotherapeutics</a> Awaits FDA Decision on Tab-cel® BLA with PDUFA Target Date Set for January 10, 2026, Potential $40 Million Milestone from Pierre Fabre Laboratories

Atara Biotherapeutics Inc., a leader in T-cell immunotherapy, has announced a significant milestone in its ongoing regulatory review process. The company has set a Prescription Drug User Fee Act (PDUFA) target action date of January 10, 2026, for its biologics license application $(BLA.AU)$ for Tabelecleucel (tab-cel® or Ebvallo™), aimed at treating Post-Transplant Lymphoproliferative Disease (PTLD). This regulatory milestone is crucial, as the approval of the BLA would trigger a $40 million milestone payment from Pierre Fabre Laboratories, enhancing Atara's financial flexibility significantly. Additionally, Atara has transferred most operational activities related to tab-cel to Pierre Fabre Laboratories. The company is also evaluating strategic options, including potential acquisitions or mergers, following the resubmission of the tab-cel BLA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atara Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-106533), on August 11, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10